A phase III clinical trial investigating the new cancer treatment nimotuzumab has started to enroll patients at approximately 60 clinical centers in Japan. The study will examine patients with locally advanced, inoperable stage III squamous cell carcinoma (SCC) of the lung, a type of non-small cell lung cancer (NSCLC). Patients will receive standard chemotherapy either with or without nimotuzumab. Produced by the pharmaceutical company Daiichi Sankyo, nimotuzumab is an antibody (a type of immune system protein) that targets a protein called EGFR, which is mutated in many cases of lung cancer.